CUE-101 combined with pembrolizumab demonstrates a 46% objective response rate and a 91.3% 12-month overall survival rate in first-line HPV+ R/M HNSCC patients.
Cue Biopharma's CUE-101, combined with pembrolizumab, demonstrated a 46% objective response rate and a 91.3% 12-month overall survival rate in head and neck cancer patients.
CUE-101 combined with pembrolizumab shows a 46% objective response rate and 91.3% 12-month overall survival in first-line HPV+ recurrent/metastatic head and neck squamous cell carcinoma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.